These results demonstrate that our assay system can interrogate multiple cellular mechanisms revealing new biology regarding the two most frequently identified gene disruptions (BSCL2 and AGPAT2) [46] leading to congenital generalized lipodystrophy. The gene discussed is AGPAT2; the disease is generalized lipodystrophy.